- Home
- RLGT vs TLSI Comparison
RLGT vs TLSI Comparison
Compare RLGT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | TLSI |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 272.3M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | TLSI |
|---|---|---|
| Price | $7.62 | $5.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 228.4K | 151.1K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $902,696,000.00 | N/A |
| Revenue This Year | $2.13 | $55.47 |
| Revenue Next Year | $5.18 | $40.05 |
| P/E Ratio | $53.79 | ★ N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $5.44 | $3.42 |
| 52 Week High | $8.50 | $7.95 |
Technical Indicators
Market Signals| Indicator | RLGT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 47.03 |
| Support Level | $5.84 | $4.90 |
| Resistance Level | $8.50 | $5.50 |
| Average True Range (ATR) | 0.33 | 0.34 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 43.06 | 46.76 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.